Equities analysts forecast that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will post $59.77 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Vanda Pharmaceuticals’ earnings, with estimates ranging from $57.10 million to $64.00 million. Vanda Pharmaceuticals posted sales of $53.04 million in the same quarter last year, which would indicate a positive year over year growth rate of 12.7%. The business is scheduled to issue its next earnings results on Wednesday, February 12th.

According to Zacks, analysts expect that Vanda Pharmaceuticals will report full-year sales of $225.97 million for the current year, with estimates ranging from $223.40 million to $230.00 million. For the next year, analysts forecast that the company will report sales of $274.20 million, with estimates ranging from $245.50 million to $327.10 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Vanda Pharmaceuticals.

Several research firms recently weighed in on VNDA. BidaskClub lowered Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, February 1st. Stifel Nicolaus restated a “hold” rating on shares of Vanda Pharmaceuticals in a report on Sunday, February 2nd. ValuEngine upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Citigroup lowered Vanda Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $19.00 target price for the company. in a report on Thursday, November 7th. Finally, Zacks Investment Research lowered Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, February 8th. Two equities research analysts have rated the stock with a sell rating and five have issued a hold rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $19.40.

VNDA traded down $0.25 on Tuesday, hitting $12.70. The company had a trading volume of 261,820 shares, compared to its average volume of 509,721. The company’s fifty day moving average price is $14.75 and its 200 day moving average price is $14.73. Vanda Pharmaceuticals has a 1-year low of $11.83 and a 1-year high of $21.41. The stock has a market cap of $689.46 million, a price-to-earnings ratio of 5.70 and a beta of 0.27.

In other Vanda Pharmaceuticals news, CFO James Patrick Kelly sold 4,020 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $15.94, for a total value of $64,078.80. Following the transaction, the chief financial officer now directly owns 205,726 shares of the company’s stock, valued at approximately $3,279,272.44. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Mihael Hristos Polymeropoulos sold 9,467 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $16.00, for a total value of $151,472.00. Following the completion of the transaction, the chief executive officer now directly owns 1,234,579 shares in the company, valued at $19,753,264. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 14,642 shares of company stock valued at $234,100. Corporate insiders own 8.20% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. PNC Financial Services Group Inc. increased its position in Vanda Pharmaceuticals by 74.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,073 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 1,316 shares during the period. Quantbot Technologies LP increased its position in Vanda Pharmaceuticals by 28.7% in the 4th quarter. Quantbot Technologies LP now owns 5,200 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 1,159 shares during the period. Meeder Asset Management Inc. increased its position in Vanda Pharmaceuticals by 1,638.3% in the 3rd quarter. Meeder Asset Management Inc. now owns 5,215 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 4,915 shares during the period. Amalgamated Bank bought a new position in Vanda Pharmaceuticals in the 4th quarter worth approximately $165,000. Finally, Victory Capital Management Inc. increased its position in Vanda Pharmaceuticals by 25.7% in the 4th quarter. Victory Capital Management Inc. now owns 10,190 shares of the biopharmaceutical company’s stock worth $167,000 after buying an additional 2,084 shares during the period. 99.50% of the stock is currently owned by institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

See Also: Cost of Debt

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.